# Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer

> **NCT06027268** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Wake Forest University Health Sciences** · enrollment: 36 (estimated)

## Conditions studied

- Metastatic Triple-Negative Breast Cancer

## Interventions

- **DRUG:** Trilaciclib
- **DRUG:** Pembrolizumab
- **DRUG:** Gemcitabine
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT06027268
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-10
- **Primary completion:** 2026-09
- **Final completion:** 2027-03
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-04-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06027268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06027268, "Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06027268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*